Search

Displaying results 731 - 740 of 10000 in total
  1. Drug

    Cisatracurium

    go.drugbank.com/drugs/DB00565
    ApprovedInvestigational

    [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release.[A253597] … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].

    Products: NİMBEX 20 MG/10 ML ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, Nimbex Forte Injection 150 mg/30 ml
  2. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

    Products: EBASTINA EG, KESTINE TABLET 10 mg
  3. Drug

    Alpha-1-proteinase inhibitor

    go.drugbank.com/drugs/DB00058
    ApprovedInvestigational

    Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.

    Synonyms: Alpha-1 MP, Wap four-disulfide core domain protein 4Products: PROLASTIN C 1000 MG IV İNFÜZYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADET, Prolastin 1000 mg - Pulver und Lösungsmittel zur Herstellung einer Infusionslösung
  4. Drug

    Norepinephrine

    go.drugbank.com/drugs/DB00368
    ApprovedInvestigational

    It is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.

    Mixtures: XYLONOR %3 NORADRENALINE ENJEKSIYONLUK SOLUSYON ICEREN KULLANIMA HAZIR 50 KARTUSProducts: N-EPI, N-EPI® 1mg/ml Concentrate for Solution for Infusion
  5. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.

    Products: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 ML
  6. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].

    Products: TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET
  7. Drug

    Propofol

    go.drugbank.com/drugs/DB00818
    ApprovedInvestigationalVet approved

    Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. … Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries

    Mixtures: Anesthesia S/I-60, Anesthesia S/I-40Products: RAPIFOL INYECCION 20 ML (PROPOFOL 10 MG/ML), PROPOFOL1% ( 10 MG / ML ).
  8. Drug

    Peginterferon beta-1a

    go.drugbank.com/drugs/DB09122
    ApprovedInvestigational

    [L5801] MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men. … [L31428] Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.

    Mixtures: Plegridy Pen, Plegridy PenCategories: Compounds used in a research, industrial, or household setting
  9. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    The FDA approved ketamine (Ketalar) in 1970. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications

    Categories: Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in Durchstechflaschen
  10. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … [A260187,A260192,A260197] Approximately 80% of myasthenia gravis patients tested positive for the AChR autoantibodies, and 40% of these AChR-negative or seronegative patients were found to have MuSK autoantibodies

    Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adet